## Brent D G Page

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3401578/publications.pdf

Version: 2024-02-01

25 papers 1,201 citations

623188 14 h-index 610482 24 g-index

26 all docs

26 docs citations

times ranked

26

2250 citing authors

#	Article	IF	CITATIONS
1	The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase. Journal of Biological Chemistry, 2022, 298, 101531.	1.6	16
2	TSLP as druggable target – a silver-lining for atopic diseases?. , 2021, 217, 107648.		33
3	The Application of Differential Scanning Fluorimetry in Exploring Bisubstrate Binding to Protein Arginine <i>N</i> â€Methyltransferase 1. FASEB Journal, 2021, 35, .	0.2	O
4	NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir. Cell Chemical Biology, 2021, 28, 1693-1702.e6.	2.5	9
5	Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. Cancers, 2021, 13, 3464.	1.7	5
6	The application of differential scanning fluorimetry in exploring bisubstrate binding to protein arginine N-methyltransferase 1. Methods, 2020, 175, 10-23.	1.9	8
7	Development of a chemical probe against NUDT15. Nature Chemical Biology, 2020, 16, 1120-1128.	3.9	14
8	To inhibit TrxR1 is to inactivate STAT3–Inhibition of TrxR1 enzymatic function by STAT3 small molecule inhibitors. Redox Biology, 2020, 36, 101646.	3.9	18
9	Validating Signal Transducer and Activator of Transcription (STAT) Protein–Inhibitor Interactions Using Biochemical and Cellular Thermal Shift Assays. ACS Chemical Biology, 2020, 15, 1842-1851.	1.6	12
10	Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death. Science Advances, 2020, 6, eaax7945.	4.7	43
11	Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells. Nature Communications, 2018, 9, 250.	5.8	56
12	STAT3 differential scanning fluorimetry and differential scanning light scattering assays: Addressing a missing link in the characterization of STAT3 inhibitor interactions. Journal of Pharmaceutical and Biomedical Analysis, 2018, 160, 80-88.	1.4	14
13	Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nature Medicine, 2017, 23, 256-263.	15.2	102
14	Identification of novel small molecules that inhibit STAT3-dependent transcription and function. PLoS ONE, 2017, 12, e0178844.	1.1	17
15	NUDT15 Hydrolyzes 6-Thio-DeoxyGTP to Mediate the Anticancer Efficacy of 6-Thioguanine. Cancer Research, 2016, 76, 5501-5511.	0.4	96
16	Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics. Molecular Cancer Therapeutics, 2016, 15, 794-805.	1.9	35
17	STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)–STAT3 pathway. Leukemia and Lymphoma, 2016, 57, 2681-2684.	0.6	16
18	Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2. Nature Communications, 2015, 6, 7871.	5.8	96

#	Article	IF	CITATIONS
19	STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget, 2015, 6, 27461-27477.	0.8	55
20	Identification of a potent salicylic acid-based inhibitor of tyrosine phosphatase PTP1B. MedChemComm, 2013, 4, 987-992.	3.5	8
21	Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9623-9628.	3.3	301
22	Small Molecule STAT5-SH2 Domain Inhibitors Exhibit Potent Antileukemia Activity. Journal of Medicinal Chemistry, 2012, 55, 1047-1055.	2.9	90
23	Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5605-5609.	1.0	57
24	Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opinion on Therapeutic Patents, 2011, 21, 65-83.	2.4	96
25	Inside Cover: Disruption of Transcriptionally Active Stat3 Dimers with Non-phosphorylated, Salicylic Acid-Based Small Molecules: Potent in vitro and Tumor Cell Activities (ChemBioChem 12/2009). ChemBioChem, 2009, 10, 1906-1906.	1.3	1